REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot173110.32687/1561-5936-2024-28-4-348-352Original ArticleClinical — economic indicators of the effectiveness of pharmacotherapy in two different therapy for psoriasis vulgarisKhokhlovAlexander L.al460935@yandex.ruSamarinaElena I.a.tet@mail.ruLileevaElena G.elileeva2006@yandex.ruYaroslavl State Medical University, Yaroslavl, Russia15122024434835215102025Copyright © 2024,2024Rational pharmacotherapy has a significant impact not only on the patient’s quality of life, but also on the cost of treatment, including the cost of therapy, both from the patient and from the government. This article is devoted to the study of systemic medications used in patients with severe and moderate plaque psoriasis, followed by a comparison of the effectiveness of the use of various medications among patients observed in dermatovenerological dispensaries of the Central Federal District. This article dynamically describes the monitored results of the use of innovative genetically engineered biological agent (GEBA) at various points of application and demonstrates the feasibility of prescribing GEBA for plaque psoriasis, both from a clinical and economic point of view.genetically engineered drugssystemic therapy for psoriasispharmacoeconomicsplaque psoriasisclinical effectivenessinterleukin inhibitorsгенно-инженерные лекарственные препаратысистемная терапия псориазафармакоэкономикабляшечный псориазклиническая эффективностьингибиторы интерлейкина1.Sokolova V. D., Sableva N. A., Mladov V. V., Tolkacheva D. G. Efficacy of targeted drugs for the treatment of adults with moderate-to-severe plaque psoriasis in the Russian Federation: a systematic literature review update. Farmacoeconomica. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):131–144. DOI: 10.17749/2070-4909/farmakoekonomika.2022.1282.Bakulev A. L., Mladov V. V., Sokolova V. D., Tolkacheva D. G. Targeted drugs in the treatment of adult patients with moderate and severe psoriasis vulgaris in the Russian Federation: the number of patients who need to be treated to achieve a response to therapy, and the costs of achieving it. Medical technologies. Evaluation and selection. 2020;4(42):58–74. DOI: 10.17116/med-tech202042041583.Yagudina R. I., Kulikova A. U., Serpik V. G. Pharmacoeconomics: textbook. Rostov-on-Don; 2017. 237 p. (In Russ.)4.Shapovalova M. A., Koretskaya L. R. ABC and VEN analyzes of drug costs and medical costs for patient treatment. Farmacoeconomica. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2014;7(1):19–21.5.Zhukova O. V., Ruina O. V., Khazov M. V. et al. Pharmacoepidemiological analysis of medication consumption in a multidepartmental hospital as an element of medical care quality management and the basis for assessing import substitution. Farmacoeconomica. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):51–58. DOI: 10.17749/2070-4909/farmakoekonomika.2022.0466.Konnov P. E., Orlov E. V., Mostovaya L. I., Arsen'eva A. A. Assessment of the Quality of Life and Efficacy of a Complex Pharmacotherapy with Anxiolytic in Patients with Chronic Actinic Dermatitis. Vestnik dermatologii i venerologii. 2019;95(6):37–43. DOI: 10.25208/0042-4609-2019-95-6-37-437.Gerasimov V. B., Khokhlov A. L., Karpov O. I. et al. Pharmaco-economics and pharmacoepidemiology — practice of acceptable solutions. Moscow; 2005. 352 p. (In Russ.)8.Wade R., Sharif-Hurst S., Dias S. Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. Syst. Rev. 2020;9(1):132. DOI: 10.1186/s13643-020-01395-6